19-05-2025
ASCO 2025: Previewing Therapeutic Updates in Advanced NSCLC
Isabel Preeshagul, DO, is eagerly anticipating ASCO 2025, especially the progress being made in advanced NSCLC within the targeted therapy space. Promising developments include treatments for KRAS G12C alterations, particularly the LOXO-RAS-20001 phase 1/2 study combining olomorasib with immunotherapy, and for EGFR exon 20 insertions, where zipalertinib is showing potential after frontline therapy.
In the HER2 space, new small-molecule tyrosine kinase inhibitors such as zongertinib, BAY 2927088, and NVL-330 are generating excitement, especially regarding their central nervous system penetration. Beyond targeted therapies, there's strong interest in antibody-drug conjugates, notably the TROPION-Lung02 study evaluating datopotamab deruxtecan in combination with pembrolizumab and chemotherapy.
